PL2295417T3 - Nowe produkty pośrednie przydatne do wytwarzania związku alfa-(n-sulfonamido)acetamidu - Google Patents

Nowe produkty pośrednie przydatne do wytwarzania związku alfa-(n-sulfonamido)acetamidu

Info

Publication number
PL2295417T3
PL2295417T3 PL10190591T PL10190591T PL2295417T3 PL 2295417 T3 PL2295417 T3 PL 2295417T3 PL 10190591 T PL10190591 T PL 10190591T PL 10190591 T PL10190591 T PL 10190591T PL 2295417 T3 PL2295417 T3 PL 2295417T3
Authority
PL
Poland
Prior art keywords
sulfonamido
novel intermediates
intermediates useful
acetamide compound
preparing alpha
Prior art date
Application number
PL10190591T
Other languages
English (en)
Inventor
Jr John E Starrett;
Kevin W Gillman
Richard E Olson
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40193955&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2295417(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PL2295417T3 publication Critical patent/PL2295417T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/15—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C311/16—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom
    • C07C311/19—Sulfonamides having sulfur atoms of sulfonamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the sulfonamide groups bound to hydrogen atoms or to an acyclic carbon atom to an acyclic carbon atom of a hydrocarbon radical substituted by carboxyl groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C237/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C237/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C253/00—Preparation of carboxylic acid nitriles
    • C07C253/30—Preparation of carboxylic acid nitriles by reactions not involving the formation of cyano groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PL10190591T 2007-10-31 2008-10-14 Nowe produkty pośrednie przydatne do wytwarzania związku alfa-(n-sulfonamido)acetamidu PL2295417T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98411807P 2007-10-31 2007-10-31
EP08843687A EP2205575B1 (en) 2007-10-31 2008-10-14 A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
EP10190591A EP2295417B1 (en) 2007-10-31 2008-10-14 Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound

Publications (1)

Publication Number Publication Date
PL2295417T3 true PL2295417T3 (pl) 2012-11-30

Family

ID=40193955

Family Applications (2)

Application Number Title Priority Date Filing Date
PL08843687T PL2205575T3 (pl) 2007-10-31 2008-10-14 Nowy związek alfa-(N-sulfonamido) acetamidowy jako inhibitor wytwarzania peptydu beta-amyloidu
PL10190591T PL2295417T3 (pl) 2007-10-31 2008-10-14 Nowe produkty pośrednie przydatne do wytwarzania związku alfa-(n-sulfonamido)acetamidu

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PL08843687T PL2205575T3 (pl) 2007-10-31 2008-10-14 Nowy związek alfa-(N-sulfonamido) acetamidowy jako inhibitor wytwarzania peptydu beta-amyloidu

Country Status (29)

Country Link
US (2) US8084477B2 (pl)
EP (3) EP2471769A1 (pl)
JP (1) JP5460605B2 (pl)
KR (1) KR20100075575A (pl)
CN (2) CN102718689A (pl)
AR (1) AR069135A1 (pl)
AT (1) ATE502022T1 (pl)
AU (1) AU2008319122A1 (pl)
BR (1) BRPI0818837A2 (pl)
CA (1) CA2704360A1 (pl)
CL (1) CL2008003271A1 (pl)
CO (1) CO6270332A2 (pl)
CY (2) CY1112337T1 (pl)
DE (1) DE602008005636D1 (pl)
DK (2) DK2295417T3 (pl)
EA (2) EA201171439A1 (pl)
ES (2) ES2361283T3 (pl)
HK (2) HK1141801A1 (pl)
HR (2) HRP20110219T1 (pl)
IL (1) IL205406A0 (pl)
MX (1) MX2010004319A (pl)
NZ (1) NZ584545A (pl)
PE (1) PE20091394A1 (pl)
PL (2) PL2205575T3 (pl)
PT (2) PT2205575E (pl)
SG (2) SG174043A1 (pl)
SI (2) SI2205575T1 (pl)
TW (1) TW200927099A (pl)
WO (1) WO2009058552A1 (pl)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI1465861T1 (sl) 2001-12-20 2009-12-31 Bristol Myers Squibb Co Alfa-(n-sulfonamido)acetamidni derivati kot beta-amiloid inhibitorji
US8093276B2 (en) * 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production
NZ594561A (en) * 2009-03-19 2013-03-28 Bristol Myers Squibb Co A novel alpha-(n-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US7977362B2 (en) 2009-03-20 2011-07-12 Bristol-Myers Squibb Company Alpha-(N-benzenesulfonamido)cycloalkyl derivatives
TW201043269A (en) * 2009-04-14 2010-12-16 Bristol Myers Squibb Co Bioavailable compositions of amorphous alpha-(N-sulfonamido)acetamide compound
US8252821B2 (en) * 2009-04-14 2012-08-28 Bristol-Myers Squibb Company Bioavailable capsule compositions of amorphous alpha-(N-sulfonamido)acetamide compound
AU2011225122B8 (en) * 2010-03-12 2013-12-12 Nippon Soda Co., Ltd. Compound containing pyridine ring and method for producing halogenated picoline derivative and tetrazolyloxime derivative
WO2012040444A2 (en) * 2010-09-24 2012-03-29 Bristol-Myers Squibb Company Treatment of patients with incipient alzheimer's disease
US9284296B2 (en) 2010-11-22 2016-03-15 Aubergine Pharmaceuticals Llc Bipyridine sulfonamide derivatives for the treatment of neurodegenerative diseases or conditions
US9249157B2 (en) 2012-09-21 2016-02-02 Bristol-Myers Squibb Company Tricyclic heterocycle compounds
US9133139B2 (en) 2012-09-21 2015-09-15 Bristol-Myers Squibb Company Fluoroalkyl-1,4-benzodiazepinone compounds
EP2897944B1 (en) 2012-09-21 2016-10-26 Bristol-Myers Squibb Company Substituted 1,5-benzodiazepinone compounds
EP2897938B1 (en) 2012-09-21 2017-03-15 Bristol-Myers Squibb Company Fluoroalkyl dibenzodiazepinone compounds
CN103058913B (zh) * 2012-12-13 2015-09-30 江苏弘和药物研发有限公司 5-氯异吲哚酮的合成方法
CN104163784B (zh) * 2014-06-20 2019-01-08 湖南天地恒一制药有限公司 一种奥拉西坦的合成工艺
RU2757276C2 (ru) 2016-12-16 2021-10-12 Пайплайн Терапьютикс, Инк. Способы лечения кохлеарной синаптопатии
WO2018201056A1 (en) 2017-04-28 2018-11-01 Novartis Ag Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
WO2018201051A1 (en) 2017-04-28 2018-11-01 Novartis Ag Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
CN107935957B (zh) * 2017-12-02 2020-08-21 江苏仁明生物科技有限公司 一种合成高纯度沙坦侧链ttbb的方法
BR112020024351A2 (pt) 2018-06-01 2021-02-23 Novartis Ag moléculas de ligação contra bcma e usos das mesmas
CN108640886A (zh) * 2018-08-01 2018-10-12 余锋 一种作为β-淀粉样肽产生的抑制剂BMS-708163的合成方法
WO2020261093A1 (en) 2019-06-24 2020-12-30 Novartis Ag Dosing regimen and combination therapies for multispecific antibodies targeting b-cell maturation antigen
CN113466367B (zh) * 2021-06-25 2023-04-14 深圳万乐药业有限公司 乌苯美司原料药中α-苯乙胺杂质检测方法
CN113816874B (zh) * 2021-10-30 2024-01-26 大连双硼医药化工有限公司 一种合成4-氰基-2-氟苄醇的工艺方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5274094A (en) * 1990-08-15 1993-12-28 British Bio-Technology Limited Production of heterobicyclic containing benzene sulfonamides
GB9202791D0 (en) * 1992-02-11 1992-03-25 British Bio Technology Compounds
US5849736A (en) * 1993-11-24 1998-12-15 The Dupont Merck Pharmaceutical Company Isoxazoline and isoxazole fibrinogen receptor antagonists
PL326700A1 (en) * 1995-11-17 1998-10-26 Warner Lambert Co Sulphonamide-based inhibitors of intercellular substance metaloproteinases
CZ16899A3 (cs) 1996-07-22 1999-08-11 Monsanto Company Thiolsulfonamidové inhibitory metaloproteázy
JPH11343279A (ja) 1998-03-16 1999-12-14 Shionogi & Co Ltd スルホンアミド誘導体およびそれらを含有するＴＮＦ―α産生抑制剤
HUP0105282A3 (en) 1999-01-27 2005-04-28 Wyeth Holdings Corp Madison Acetylenic sulfonamide thiol tace inhibitors process for their preparation and pharmaceutical compositions containing the same
US6313123B1 (en) * 1999-01-27 2001-11-06 American Cyanamid Company Acetylenic sulfonamide thiol tace inhibitors
MXPA01008606A (es) 1999-02-26 2003-05-05 Merck & Co Inc Compuestos de sulfonamida novedosos y uso de los mismos.
US6541467B1 (en) * 2000-04-14 2003-04-01 Corvas International, Inc. Thrombin inhibitors having a lactam at P3
US20020115640A1 (en) * 2000-11-30 2002-08-22 Claiborne Akiyo K. Farnesyltransferase inhibitors
DE60239078D1 (de) * 2001-12-14 2011-03-10 Raytheon Co Präzise justierte linsenstruktur und eine methode zur herstellung derselben
SI1465861T1 (sl) * 2001-12-20 2009-12-31 Bristol Myers Squibb Co Alfa-(n-sulfonamido)acetamidni derivati kot beta-amiloid inhibitorji
KR20040086465A (ko) * 2002-02-28 2004-10-08 아스트라제네카 아베 화합물
DE60313844T2 (de) * 2003-03-20 2008-01-31 Santhera Pharmaceuticals (Schweiz) Ag Substituierte Piperidin- und Piperazin-Derivative als Melanocortin-4 Receptor Modulatoren
NZ542468A (en) * 2003-03-31 2009-01-31 Wyeth Corp Fluoro- and trifluoroalkyl-containing heterocyclic sulfonamide inhibitors of beta amyloid production and derivatives thereof
US7144894B2 (en) * 2004-09-23 2006-12-05 Bristol-Myers Squibb Company Sulfonamide bicyclic compounds
EP1984347A1 (en) * 2006-02-17 2008-10-29 Wyeth a Corporation of the State of Delaware Selective n-sulfonylation of 2-amino trifluoroalkyl substituted alcohols
AR059518A1 (es) * 2006-02-17 2008-04-09 Wyeth Corp Metodos para preparar alcoholes sustituidos con sulfonamidas y sus compuestos intermedios
WO2008112249A1 (en) 2007-03-13 2008-09-18 Trustees Of Columbia University In The City Of New York Synergistic interaction of notch-1 inhibitors with glucocorticoids
WO2009005688A2 (en) 2007-06-29 2009-01-08 Trustees Of Columbia University In The City Of New York Activating mutations in notch-1
US8093276B2 (en) 2007-10-31 2012-01-10 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compound as an inhibitor of beta amyloid peptide production
US8044077B2 (en) * 2009-03-19 2011-10-25 Bristol-Myers Squibb Company Alpha-(N-sulfonamido)acetamide compounds incorporating deuterium as inhibitors of beta amyloid peptide production

Also Published As

Publication number Publication date
PL2205575T3 (pl) 2011-09-30
HK1155161A1 (en) 2012-05-11
BRPI0818837A2 (pt) 2015-04-22
HRP20120703T1 (hr) 2012-09-30
EP2471769A1 (en) 2012-07-04
EA201171439A1 (ru) 2012-05-30
US8084477B2 (en) 2011-12-27
SI2295417T1 (sl) 2012-11-30
US20090111858A1 (en) 2009-04-30
AU2008319122A1 (en) 2009-05-07
MX2010004319A (es) 2010-04-30
SG174043A1 (en) 2011-09-29
SI2205575T1 (sl) 2011-07-29
ES2361283T3 (es) 2011-06-15
JP5460605B2 (ja) 2014-04-02
CL2008003271A1 (es) 2009-07-10
ATE502022T1 (de) 2011-04-15
JP2011502153A (ja) 2011-01-20
HRP20110219T1 (hr) 2011-04-30
TW200927099A (en) 2009-07-01
PT2205575E (pt) 2011-05-23
ES2390042T3 (es) 2012-11-06
DK2205575T3 (da) 2011-07-11
US8350084B2 (en) 2013-01-08
CO6270332A2 (es) 2011-04-20
US20120088925A1 (en) 2012-04-12
CN101910141B (zh) 2012-12-19
PE20091394A1 (es) 2009-09-25
AR069135A1 (es) 2009-12-30
EP2205575A1 (en) 2010-07-14
EA016447B1 (ru) 2012-05-30
SG174044A1 (en) 2011-09-29
CN102718689A (zh) 2012-10-10
DK2295417T3 (da) 2012-10-15
KR20100075575A (ko) 2010-07-02
CY1113346T1 (el) 2016-06-22
DE602008005636D1 (de) 2011-04-28
EP2295417B1 (en) 2012-07-04
EP2205575B1 (en) 2011-03-16
PT2295417E (pt) 2012-09-26
CY1112337T1 (el) 2015-12-09
NZ584545A (en) 2011-04-29
HK1141801A1 (en) 2010-11-19
EP2295417A1 (en) 2011-03-16
CN101910141A (zh) 2010-12-08
WO2009058552A1 (en) 2009-05-07
IL205406A0 (en) 2010-12-30
EA201000714A1 (ru) 2010-10-29
CA2704360A1 (en) 2009-05-07

Similar Documents

Publication Publication Date Title
HK1155161A1 (en) Novel intermediates useful for preparing alpha-(n-sulfonamido)acetamide compound
HK1129221A1 (en) Novel compounds
EP2152081A4 (en) NEW CONNECTIONS
EP2146745A4 (en) NOVEL CONNECTIONS
EP2079466A4 (en) SUBSTITUTED INDOLE COMPOUNDS
GB0705882D0 (en) Novel compounds
HK1132268A1 (en) Novel anxiolytic compounds
GB0705803D0 (en) Novel compounds
GB0710680D0 (en) Novel crystalline form of olmesartan medoxmil
PT2173710E (pt) Nova forma cristalina
ZA200806859B (en) Novel crystalline compounds
IL195092A0 (en) Crystalline form of (s)-1-phenylethylammonium (r)-diphenyl-methanesulphinyl-acetate
HU0800755D0 (en) Novel crystalline forms
GB0703973D0 (en) Novel compounds
GB0806596D0 (en) Novel compounds A3
GB0707722D0 (en) Novel compounds A3
GB0608095D0 (en) Novel compounds A3
GB0703630D0 (en) Novel compounds
GB0703404D0 (en) Novel compounds
GB0700077D0 (en) Novel compounds
GB0703631D0 (en) Novel compounds
GB0703677D0 (en) Novel compounds
GB0700996D0 (en) Novel compounds
GB0701638D0 (en) Novel compounds
GB0704012D0 (en) Novel compounds